Tamarindus indica stem bark extract attenuates depression and spatial memory deficits in mice

Year 2025, Volume: 3 Issue: 2, 50 - 57, 31.08.2025

Suleiman Yunusa , Faiza Zubairu Usman Adamu Garkuwa Yahaya Mohammed Katagum

https://doi.org/10.62425/rtpharma.1705387

Abstract

Title: Tamarindus indica stem bark extract attenuates depression and spatial memory deficits in mice
Running title: Tamarindus indica reversed depression and memory loss in mice
Abstract
Objective: Depression is a prevalent psychiatric disorder that affects individuals from all walks of life, impairing cognitive functions and daily life. This study investigated the potential therapeutic effects of Tamarindus indica stem bark extract on depression and spatial memory deficits in ketamine-exposed mice. Method: Tamarindus indica stem bark extract was extracted using 90% v/v methanol. The extract was screened for phytochemicals followed by acute toxicity study using Lorke’s method. Schizophrenic mice models were developed following ketamine administration at sub-anesthetic dose (20 mg/kg) daily for seven (7) days, consecutively. The mice were randomly assigned into five groups (n = 5 per group) as follows: Group I received normal saline (10 ml/kg, i.p.); Groups II, III, and IV received graded doses of Tamarindus indica extract at 400, 200, and 100 mg/kg, respectively; and Group V received risperidone (2.0 mg/kg, i.p.).Tail suspension test and Forced swimming test were used to assess depression while Y maze was used to assess spatial working memory. Results: The extract showed the presence of glycosides, saponins, phenols, and alkaloids. The LD50 value obtained was approximately 2,150 mg/kg. Tamarindus indica stem bark extract effectively improved the depressive symptoms by significantly (P < 0.0001) reversing the immobility time with the 400 mg/kg dose exhibiting the highest activity compared to control group in both TST and FST. Also, Tamarindus indica stem bark extract significantly (P < 0.0001) increased the number of spontaneous alternation compared to the control group. Conclusion: Tamarindus indica stem bark extract may effectively reverse depression and memory impairment in ketamine model of schizophrenia.

Keywords: Tamarindus indica, Depression, Cognitive impairment, Ketamine-induced model.

Keywords

Tamarindus indica , Depression , Cognitive impairment , Ketamine-induced model.

References

• Ahmad, N. I., Mustar, S., Rahman, S. A., & Salim, R. J. M. (2024). Tamarindus indica L. Its Phytochemicals and Health Related Issues. In Science of Spices and Culinary Herbs-Latest Laboratory, Pre-clinical, and Clinical Studies: Volume 6 (pp. 93-146). Bentham Science Publishers.
• Alaka Kar G.B., Dr. Susanta Kumar Rout and Debashisa Mishra (2019). Assessment of Neuropharmacological Activities of. 8(3), 1480–1495. https://doi.org/10.20959/wjpr20193-14433.
• Badmaev, V., Vik, H., Stohs, S. J., & Galluzzo, F. (2018). Safety and toxicological evaluation of NXT15906F6 (TamaFlex®) A food-derived botanical composition containing standardized extracts of Tamarindus indica seeds and Curcuma longa rhizomes. Toxicology Research and Application, 2, 2397847317749240.
• Beere, V., Choudhary, K., Bisht, P., Rai, A., & Kumar, N. (2024). Prediction of molecular targets for antidepressant potential of hydroalcoholic extract of Tamarindus indica using network pharmacology approach and evaluating its efficacy in Chronic Unpredictable Mild Stress model in mice. 3 Biotech, 14(10), 232.
• Brakatselos, C., Polissidis, A., Ntoulas, G., Asprogerakas, M. Z., Tsarna, O., Vamvaka-Iakovou, A., ... & Antoniou, K. (2025). Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats. Neuropsychopharmacology, 50(2), 388-400.
• Callahan, P. M., Terry Jr, A. V., Peitsch, M. C., Hoeng, J., & Koshibu, K. (2021). Differential effects of alkaloids on memory in rodents. Scientific reports, 11(1), 9843.
• Chatterjee M, Verma R, Ganguly S, Palit G. Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice. Neuropharmacology. 2012 Nov;63(6):1161–71.
• Ebrahimi, M., Ahangar, N., Zamani, E., & Shaki, F. (2023). L‐Carnitine Prevents Behavioural Alterations in Ketamine‐Induced Schizophrenia in Mice: Possible Involvement of Oxidative Stress and Inflammation Pathways. Journal of Toxicology, 2023(1), 9093231.
• GBD 2019 Mental Disorders Collaborators. (2022). Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Psychiatry, 9(2), 137-150.
• Galkin, S. A., Peshkovskaya, A. G., Simutkin, G. G., Vasil’eva, S. N., Roshchina, O. V., Ivanova, S. A., & Bokhan, N. A. (2020). Impairments to the functions of spatial working memory in mild depression and their neurophysiological correlates. Neuroscience and Behavioral Physiology, 50(7), 825-829.
• Gurung, M., & Shristy, S. (2023). Effect of depression on daily life of adults.
• Farooq, S., Munir, R., Imtiaz, K., Sehar, S., Khurshid, A., Yunus, N., ... & Fang, N. (2022). Phytochemical investigation and antioxidant activities of tamarind (Tamarindus indica L.). Notulae Botanicae Horti Agrobotanici Cluj-Napoca, 50(4), 12892-12892.
• Foyet, H. S., Deffo, S. T., Yewo, P. K., Antioch, I., Zingue, S., Asongalem, E. A., Kamtchouing, P., & Ciobica, A. (2018). Ficus sycomorus extract reversed behavioral impairment and brain oxidative stress induced by unpredictable chronic mild stress in rats. 2017, 1–15. https://doi.org/10.1186/s12906-017-2012-9.
• Greenamyre JT, Maragos WF, Albin RL, et al. (1988) Glutamate transmission and toxicity in alzheimer's disease. Prog. Neuropsychopharmacol 12: 421–430.
• Hodge HC, Sterner JH. Tabulation of Toxicity Classes. American Industrial Hygiene Association Quarterly. 1949 Dec;10(4):93–6.
• Lahti, A. C., Koffel, B., Laporte, D., & Tamminga, C. A. (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology, 13(1). https://doi.org/10.1016/0893-133X(94)00131-I
• Li, Y., Liu, L., Wang, E., Zhang, H., Dou, S., Tong, L., ... & Shi, D. (2016). Abnormal neural network of primary insomnia: evidence from spatial working memory task fMRI. European neurology, 75(1-2), 48-57.
• Lorke, D. (1983). A New Approach to Practical Acute Toxicity Testing. Journal of Archives of Toxicology.54:275-287. McCutcheon, R. A., Keefe, R. S. E., & McGuire, P. K. (2023). Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. In Molecular Psychiatry. https://doi.org/10.1038/s41380-023-01949-9 National Institute of Health (NIH), (1985). Guide for the care and use of laboratory animals:DHEW Publication, revised, Office of Science and Health Reports, DRR / NIH, Bethesda, USA.
• Porsolt, R.D, LePichon, M., Jalfre, M. (1977). Depression: A new animal model sensitive to antidepressant treatment. European journal of pharmacology, 266, 730-732.
• Rizvi, A., Safwi, S. R., & Usmani, M. A. (2024). Schizophrenia: Disability, clinical insights, and management. In The Palgrave encyclopedia of disability (pp. 1-12). Cham: Springer Nature Switzerland.
• Schep, L. J., Slaughter, R. J., Watts, M., Mackenzie, E., & Gee, P. (2023). The clinical toxicology of ketamine. Clinical Toxicology, 61(6), 415-428.
• Takeshi et al. (2009). Disruptions in spatial working memory, but not short-term memory, induced by repeated ketamine exposure, Progress in Neuro-Psychopharmacology and Biological Psychiatry, Volume 33 (4), 668-675. Trease, G.E and Evans, M.C (2009). Phytochemistry In: Textbook of Pharmacognosy. Sixteenth Edition. WB Sanders Company Ltd. London, UK, 224-343.
• Uno, Y., & Coyle, J. T. (2019). Glutamate hypothesis in schizophrenia. Psychiatry and Clinical Neurosciences, 73(5), 204–215. https://doi.org/10.1111/pcn.12823.
• Yogeesha, A., & Krishnakumar, G. (2023). Ethnobotanical study of medicinal plants used in the treatment of neurological disorders in the Western Ghats region of Dakshina Kannada district, Karnataka, India. Ethnobotany Research and Applications, 26, 1-30.
• Zhang, T., Liu, C., Zhong, N., Wang, Y., Huang, Y., & Zhang, X. (2024). Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways. International Journal of Molecular Sciences, 25(19). https://doi.org/10.3390/ijms251910668